Global Penny Stocks To Watch In August 2026

As global markets navigate a complex landscape marked by easing inflation concerns and fluctuating oil prices, investors are keenly observing opportunities across various sectors. For those interested in smaller or newer companies, penny stocks—despite their somewhat outdated label—remain an intriguing area of investment due to their affordability and potential for growth. This article will explore several penny stocks that exhibit financial strength, offering investors the chance to uncover potential value in these under-the-radar companies.

Let's uncover some gems from our specialized screener.

Bank Of Sharjah P.J.S.C (ADX:BOS)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Bank Of Sharjah P.J.S.C. offers commercial and investment banking products and services in the United Arab Emirates, with a market cap of AED3.84 billion.

Operations: The company generates revenue from its Commercial Banking segment, which accounts for AED757.97 million, and its Investment and Treasury segment, contributing AED239.08 million.

Market Cap: AED3.84B

Bank Of Sharjah P.J.S.C. demonstrates a compelling profile for those exploring penny stocks, with its price-to-earnings ratio of 4.7x indicating good value compared to the AE market average. The bank has shown robust earnings growth, increasing by 70.7% over the past year, and maintains stable weekly volatility at 3%. However, it faces challenges such as a high level of bad loans at 7.5% and an unstable dividend track record. Recent earnings reports reveal improved net income and interest income for Q2 and H1 of 2026, reflecting ongoing profitability despite potential future earnings decline forecasts.

• Unlock comprehensive insights into our analysis of Bank Of Sharjah P.J.S.C stock in this financial health report.
• Gain insights into Bank Of Sharjah P.J.S.C's future direction by reviewing our growth report.

Shaanxi Beiyuan Chemical Industry Group (SHSE:601568)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Shaanxi Beiyuan Chemical Industry Group Co., Ltd. operates in the chemical industry and has a market cap of CN¥14.70 billion.

Operations: Revenue Segments: No specific revenue segments have been reported.

Market Cap: CN¥14.7B

Shaanxi Beiyuan Chemical Industry Group presents an intriguing case for penny stock investors, trading at 52% below its estimated fair value. Despite a market cap of CN¥14.70 billion and no debt, the company faces challenges with declining earnings over the past five years and a recent large one-off loss of CN¥92.2 million impacting financial results. Its short-term assets comfortably cover both short- and long-term liabilities, but profit margins have decreased from 3% to 0.5%. The management team is relatively inexperienced, potentially affecting strategic decisions moving forward.

• Click here and access our complete financial health analysis report to understand the dynamics of Shaanxi Beiyuan Chemical Industry Group.
• Understand Shaanxi Beiyuan Chemical Industry Group's track record by examining our performance history report.

Sichuan Hebang Biotechnology (SHSE:603077)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Sichuan Hebang Biotechnology Corporation Limited operates in the agricultural, chemical, and new material sectors with a market cap of CN¥18.79 billion.

Operations: Sichuan Hebang Biotechnology Corporation Limited has not reported any specific revenue segments.

Market Cap: CN¥18.79B

Sichuan Hebang Biotechnology's recent financial performance shows mixed results for penny stock investors. The company reported half-year sales of CN¥2.89 billion, down from CN¥3.92 billion the previous year, yet net income rose significantly to CN¥380.16 million from CN¥51.77 million, indicating improved profitability despite declining revenues. Trading at 40.9% below its estimated fair value suggests potential undervaluation; however, its negative return on equity and increasing debt-to-equity ratio over five years highlight financial challenges. Short-term assets exceed liabilities comfortably, and interest payments are well covered by EBIT (5.5x), offering some stability amidst volatility concerns (6%).

• Click to explore a detailed breakdown of our findings in Sichuan Hebang Biotechnology's financial health report.
• Assess Sichuan Hebang Biotechnology's previous results with our detailed historical performance reports.

Key Takeaways

• Unlock our comprehensive list of 3,623 Global Penny Stocks by clicking here.
• Curious About Other Options? Trump has pledged to "unleash" American oil and gas and these 23 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com